RYTM

Rhythm Pharmaceuticals
RYTM

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$3.78B
EV
$3.72B
Shares Outstanding
67.26M
Beta
2.32

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$78.33
P/E 2025E
-
P/Revenue 2025E
20.62x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Rhythm Pharmaceuticals, Inc.

gainify
RYTM

Rhythm Pharmaceuticals, Inc.

RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), ...

Sector

Healthcare

Industry

Biotechnology

CEO

Meeker, David

Employees

283

IPO Date

2017-10-09

Headquarters

222 Berkeley Street, 12th Floor, Boston, Massachusetts, 02116, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved